Skip to content
DataLookout
Menu

Krascendo 2NCT06793215

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 24 versions: 18 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 288 → 299 locations
  2. Minor Trial sites expanded: 280 → 288 locations
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 4 of 9 entries
  3. Minor Trial sites expanded: 268 → 280 locationsv22
  4. Minor Trial sites expanded: 260 → 268 locationsv21
  5. Minor Trial sites expanded: 251 → 260 locationsv20
  6. Minor Trial sites expanded: 240 → 251 locationsv19
  7. Minor Trial sites expanded: 217 → 240 locationsv18
  8. Minor Trial sites expanded: 195 → 217 locationsv17
  9. Minor Study sites: 180 to 195v16
  10. Minor Study sites: 151 to 180v15
  11. Minor Study sites: 105 to 151v14
  12. Minor Study sites: 63 to 105v13
  13. Minor Study sites: 32 to 63
    • Start date changed from estimate of Dec 1, 2025 to Oct 24, 2025
    v12
  14. Minor Study sites: 10 to 32v11
  15. Minor Study sites: 6 to 10v10
  16. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 6
    • Study completion date: Oct 1, 2030 to Oct 31, 2030
    v9
  17. Notable Primary completion date: Apr 28, 2028 to Nov 30, 2028
    • Start date: May 1, 2025 to Dec 1, 2025
    • Study completion date: Feb 9, 2030 to Oct 1, 2030
    v5
  18. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-Free Survival (PFS)
Timeframe: Up to approximately 5 years
Overall Survival (OS)
Timeframe: Up to approximately 5 years

Secondary (9)

Objective Response
Change from Baseline on the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Supplemental Lung Cancer Module (EORTC QLQ-LC13) Cough Scale
Change from Baseline on the EORTC Quality of Life Questionnaire (QLQ-C30) Dyspnea Item and Physical Functioning Scale
Duration of Response (DOR)
Percentage of Participants with Adverse Events (AEs)
Show 4 moreShow less
Number of Participants Reporting Presence, Frequency, Severity, and/or Degree of Interference with Daily Function of Symptomatic Treatment Toxicities Assessed by NCI Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Change from Baseline in the Severity of Selected Symptomatic Treatment Toxicities as Assessed Through use of the NCI PRO-CTCAE
Frequency of Participants' Response of the Degree they are Troubled with Treatment Symptoms, as Assessed Through use of the single-item EORTC Item List (IL46)
Change from Baseline on the EORTC QLQ-C30 and QLQ-LC13 Functional and Global Health Status Score/Quality of Life Score (GHS/QoL)

Arms and interventions

Divarasib + PembrolizumabExperimental

Participants will receive divarasib orally, once daily (QD) and pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W)

Pembrolizumab + Pemetrexed + Carboplatin or CisplatinActive comparator

Participants will receive pembrolizumab, pemetrexed and carboplatin or cisplatin via IV infusion Q3W

Drugs: Divarasib, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin

Sites

299 sites in 28 countries

United States 69, Germany 26, Japan 20, China 19, Italy 16, Spain 15, France 14, United Kingdom 12, Poland 10, Canada 9, Australia 8, Belgium 8, Brazil 7, Greece 7, Netherlands 7, Taiwan 7, South Korea 6, Argentina 5, Denmark 5, Hong Kong 4, Hungary 4, Ireland 4, Portugal 4, Switzerland 4, South Africa 3, Mexico 2, New Zealand 2, Singapore 2